CMPX — Compass Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1738021 ·
Last close
$0.61
Market Cap
$109.26M
52W High
$6.88
52W Low
$0.57
ADV30
2,611,959
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -28,800,000 | -27,171,000 | 174,498,000 | 41,469,000 | 31,928,000 |
| Jun 2026 | 0 | — | -26,979,000 | -25,154,000 | 190,173,000 | 35,453,000 | 24,124,000 |
| Mar 2026 | 0 | — | -20,299,000 | -18,317,000 | 205,170,000 | 55,168,000 | 18,697,000 |
| Dec 2025 | 0 | — | -17,990,000 | -15,716,000 | 219,588,000 | 30,643,000 | 22,797,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-61,578,000
Investing CF
$52,407,000
Financing CF
$4,428,000
CapEx
$-371,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.47
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-501,814,000
Inventory
—
Receivables
—
ST Investments
$121,589,000
EBIT TTM
$-94,068,000
Pretax Income TTM
$-86,358,000
Interest Exp TTM
—
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -72,839,000 | -66,489,000 | 219,588,000 | 22,797,000 | 196,791,000 | -49,143,000 |
| Dec 2024 | 850,000 | -56,625,000 | -49,375,000 | 140,403,000 | 15,170,000 | 125,233,000 | -44,855,000 |
| Dec 2023 | 0 | -50,363,000 | -42,494,000 | 156,875,000 | 8,337,000 | 148,538,000 | -40,618,000 |
| Dec 2022 | 0 | -41,655,000 | -39,225,000 | 199,645,000 | 18,007,000 | 181,638,000 | -34,125,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-73,446,000
OpCashFlow TTM
—
Assets (Latest)
$190,173,000
Forward EPS
$-0.59
Max Pain — expiry 2026-12-18
max pain strike: $1.00 · spot: $0.61 · call oi: 9,412 · put oi: 513
Expected Move to 2026-12-18:
±$0.10
(16.37%) —
implied range
$0.51 –
$0.71
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MOLN | MOLECULAR PARTNERS AG | $109.55M | $2.86 | — |
| LENZ | LENZ Therapeutics, Inc. | $109.97M | $3.50 | — |
| CRDL | Cardiol Therapeutics Inc. | $113.53M | $0.97 | — |
| ENGN | enGene Therapeutics Inc. | $115.27M | $1.72 | — |
| ZURA | Zura Bio Ltd | $99.70M | $1.03 | — |
News headlines (Yahoo Finance, 1h cache)
Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update
2026-11-09 13:00 · Yahoo
Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting
2026-11-06 14:00 · Yahoo
Compass Therapeutics to Participate in Upcoming November Investor Events
2026-11-02 14:00 · Yahoo
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-14 20:30 · Yahoo
Compass Therapeutics (CMPX) Stock Fair Value Falls After Tovecimig Regulatory Concerns
2026-10-14 02:13 · Yahoo
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’
2026-09-23 13:44 · Yahoo
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
2026-09-22 23:07 · Yahoo
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
2026-09-22 18:02 · Yahoo
CMPX Stock Crashes To Over 2-Year Lows — Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing
2026-09-22 14:43 · Yahoo
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
2026-07-17 14:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.